

Product Name	: Acalabrutinib
Synonyms	: ACP-196; APC196
Cat No.	: M11758
CAS Number	: 1420477-60-6
Molecular Formula	: C ₂₆ H ₂₃ N ₇ O ₂
Formula Weight	: 465.51
Chemical Name	: Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-
Description	A novel, irreversible, covalent second-generation BTK inhibitor with IC₅₀ of 3 nM; more potent and selective than ibrutinib, and does not inhibit EGFR, Itk or Txk; inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells; inhibits anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED₅₀ of 0.34 mg/kg in mice; has promising safety and efficacy profiles for CLL treatment; orally active. Blood Cancer Approved
Pathway	: Tyrosine Kinase
Target	: BTK
Receptor	: BTK
Solubility	: DMSO: ≥ 31 mg/mL
SMILES	: <chem>O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Byrd JC, et al. N Engl J Med. 2016 Jan 28;374(4):323-32. | 2. Herman SEM, et al. Clin Cancer Res. 2017 Jul 15;23(14):3734-3743. | 3. Niemann CU, et al. Clin Cancer Res. 2017 Jun 23. pii: clincanres.0650.2017.

